nach oben

29.04.2024 | Original Article

Effect of pre-transplantation use of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in kidney transplant recipients—propensity score-matched analysis

verfasst von: Jaeyun Lee, Chan-Young Jung, Hyosang Kim, Hwa Jung Kim, Youngmin Ko, Hyunwook Kwon, Sung Shin, Young Hoon Kim, Su-Kil Park, Chung Hee Baek

Erschienen in: Journal of Nephrology

Einloggen, um Zugang zu erhalten

Abstract

Background

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ACEi/ARBs) can cause acute kidney injury under dehydratation or in hemodynamically unstable conditions. Regarding kidney transplantation (KT), the risk of using ACEi/ARBs before surgery is not well established. Therefore, we evaluated the clinical outcomes to determine the effect of preoperative use of ACEi/ARBs on KT.

Methods

We retrospectively collected 1187 patients who received living-donor KT between January 2017 and December 2021. We conducted a propensity score-matched analysis between the ACEi/ARB(+) and ACEi/ARB(–) groups and evaluated the effects of ACEi/ARBs on delayed graft function, post-KT renal function, hyperkalemia events, rejection, and graft survival.

Results

The ACEi/ARB(+) group showed a similar incidence of delayed graft function as the ACEi/ARB(–) group (1.8% vs. 1.0%, P = 0.362). The risk of delayed graft function was not upregulated in the ACEi/ARB(+) group after propensity score-matching (odds ratio: 0.50, 95% confidence interval (CI) 0.13–2.00). Postoperative creatinine levels and the slope of creatinine levels after KT also were not significantly different between the two groups (creatinine slope from POD#0 to POD#7: – 0.73 ± 0.35 vs. – 0.75 ± 0.32 mg/dL/day, P = 0.464). Hyperkalemia did not occur more often in the ACEi/ARB(+) group than in the ACEi/ARB(–) group during perioperative days. Rejection-free survival (P = 0.920) and graft survival (P = 0.621) were not significantly different between the two groups.

Conclusions

In KT, the preoperative use of ACEi/ARBs did not significantly affect clinical outcomes including delayed graft function, postoperative renal function, hyperkalemia events, incidence of rejection, and graft survival rates compared to the patients who did not receive ACEi/ARBs.

Graphical abstract

Nur mit Berechtigung zugänglich

Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, Ramirez A, Schlaich M, Stergiou GS, Tomaszewski M et al (2020) 2020 International Society of Hypertension global hypertension practice guidelines. J Hypertens 38:982–1004. https://doi.org/10.1097/HJH.0000000000002453CrossRefPubMed

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A et al (2018) 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 39:3021–3104. https://doi.org/10.1093/eurheartj/ehy339CrossRefPubMed

Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members (2013) Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158:825–830. https://doi.org/10.7326/0003-4819-158-11-201306040-00007CrossRefPubMed

Feidakis A, Panagiotou MR, Tsoukakis E, Bacharaki D, Gounari P, Nikolopoulos P, Marathias KP, Lionaki S, Vlahakos D (2021) Impact of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on acute kidney injury in emergency medical admissions. J Clin Med 10:412. https://doi.org/10.3390/jcm10030412CrossRefPubMedPubMedCentral

Tomson C, Tomlinson LA (2019) Stopping RAS inhibitors to minimize AKI: more harm than good? Clin J Am Soc Nephrol 14:617–619. https://doi.org/10.2215/CJN.14021118CrossRefPubMedPubMedCentral

Arora P, Rajagopalam S, Ranjan R, Kolli H, Singh M, Venuto R, Lohr J (2008) Preoperative use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers is associated with increased risk for acute kidney injury after cardiovascular surgery. Clin J Am Soc Nephrol 3:1266–1273. https://doi.org/10.2215/CJN.05271107CrossRefPubMedPubMedCentral

Thakar CV, Kharat V, Blanck S, Leonard AC (2007) Acute kidney injury after gastric bypass surgery. Clin J Am Soc Nephrol 2:426–430. https://doi.org/10.2215/CJN.03961106CrossRefPubMed

Coca SG, Garg AX, Swaminathan M, Garwood S, Hong K, Thiessen-Philbrook H, Passik C, Koyner JL, Parikh CR, Tribe-Aki Consortium (2013) Preoperative angiotensin-converting enzyme inhibitors and angiotensin receptor blocker use and acute kidney injury in patients undergoing cardiac surgery. Nephrol Dial Transplant 28:2787–2799. https://doi.org/10.1093/ndt/gft405CrossRefPubMedPubMedCentral

STARSurg Collaborative (2018) Association between peri-operative angiotensin-converting enzyme inhibitors and angiotensin-2 receptor blockers and acute kidney injury in major elective non-cardiac surgery: a multicentre, prospective cohort study. Anaesthesia 73:1214–1222. https://doi.org/10.1111/anae.14349CrossRef

10.

van Diepen S, Norris CM, Zheng Y, Nagendran J, Graham MM, Gaete Ortega D, Townsend DR, Ezekowitz JA, Bagshaw SM (2018) Comparison of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker management strategies before cardiac surgery: a pilot randomized controlled registry trial. J Am Heart Assoc 7:e009917. https://doi.org/10.1161/JAHA.118.009917CrossRefPubMedPubMedCentral

11.

Bonavia A, Javaherian M, Skojec AJ, Chinchilli VM, Mets B, Karamchandani K (2019) Angiotensin axis blockade, acute kidney injury, and perioperative morbidity in patients undergoing colorectal surgery: a retrospective cohort study. Medicine (Baltimore) 98:e16872. https://doi.org/10.1097/MD.0000000000016872CrossRefPubMed

12.

Lim MA, Bloom RD (2020) Medical therapies to reduce delayed graft function and improve long-term graft survival: are we making progress? Clin J Am Soc Nephrol 15:13–15. https://doi.org/10.2215/CJN.13961119CrossRefPubMed

13.

Mannon RB (2018) Delayed graft function: the AKI of kidney transplantation. Nephron 140:94–98. https://doi.org/10.1159/000491558CrossRefPubMed

14.

Hoorn EJ, Walsh SB, McCormick JA, Zietse R, Unwin RJ, Ellison DH (2012) Pathogenesis of calcineurin inhibitor-induced hypertension. J Nephrol 25:269–275. https://doi.org/10.5301/jn.5000174CrossRefPubMedPubMedCentral

15.

Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer WC, Curhan GC, Oberbauer R (2006) Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 17:889–899. https://doi.org/10.1681/ASN.2005090955CrossRefPubMed

16.

Hernandez D, Muriel A, Abraira V, Perez G, Porrini E, Marrero D, Zamora J, Gonzalez-Posada JM, Delgado P, Rufino M, Torres A (2012) Renin-angiotensin system blockade and kidney transplantation: a longitudinal cohort study. Nephrol Dial Transplant 27:417–422. https://doi.org/10.1093/ndt/gfr276CrossRefPubMed

17.

Formica RN Jr, Friedman AL, Lorber MI, Smith JD, Eisen T, Bia MJ (2006) A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period. Nephrol Dial Transplant 21:1389–1394. https://doi.org/10.1093/ndt/gfk058CrossRefPubMed

18.

Stevens KK, Patel RK, Clancy M, Jardine AG (2010) Angiotensin blockade is associated with early graft dysfunction after live donor renal transplantation. Transplantation 89:707–709. https://doi.org/10.1097/TP.0b013e3181c892f2CrossRefPubMed

19.

Israili ZH (2000) Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 14(Suppl 1):S73-86. https://doi.org/10.1038/sj.jhh.1000991CrossRefPubMed

20.

Von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. https://doi.org/10.1016/j.jclinepi.2007.11.008

Titel: Effect of pre-transplantation use of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in kidney transplant recipients—propensity score-matched analysis
verfasst von: Jaeyun Lee
Chan-Young Jung
Hyosang Kim
Hwa Jung Kim
Youngmin Ko
Hyunwook Kwon
Sung Shin
Young Hoon Kim
Su-Kil Park
Chung Hee Baek
Publikationsdatum: 29.04.2024
Verlag: Springer International Publishing
Erschienen in: Journal of Nephrology
Print ISSN: 1121-8428
Elektronische ISSN: 1724-6059
DOI: https://doi.org/10.1007/s40620-024-01938-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen